DANIEL GARDNER: Open Payments
NPI 1275913279 · DAPHNE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,472 in 144 payments from 23 companies in 2025. Trend: 2023 $2,260 · 2024 $2,692 · 2025 $3,472
Food & beverage: $3,387Education: $85
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 24 | $637 |
| Regeneron Healthcare Solutions, Inc. | 16 | $425 |
| Genentech USA, Inc. | 12 | $320 |
| GENZYME CORPORATION | 12 | $268 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $258 |
| Novartis Pharmaceuticals Corporation | 11 | $231 |
| Incyte Corporation | 6 | $150 |
| GlaxoSmithKline, LLC. | 9 | $148 |
| Verona Pharma, Inc. | 7 | $147 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $139 |
Products named: DUPIXENT, TEZSPIRE, XOLAIR, CUVITRU, OPZELURA, Ohtuvayre, NEFFY, Sunosi.
Industry payments across AL — which companies pay providers there.
